Taiwan · Delayed Price · Currency is TWD Welgene Biotech Statistics
Total Valuation
Welgene Biotech has a market cap or net worth of TWD 429.96 million. The enterprise value is 450.71 million.
| Market Cap | 429.96M |
| Enterprise Value | 450.71M |
Important Dates
The next estimated earnings date is Monday, August 10, 2026.
| Earnings Date | Aug 10, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Welgene Biotech has 23.30 million shares outstanding.
| Current Share Class | 23.30M |
| Shares Outstanding | 23.30M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 10.49% |
| Owned by Institutions (%) | n/a |
| Float | 5.96M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.13 |
| PB Ratio | 1.54 |
| P/TBV Ratio | 1.67 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 20.84 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1.18 |
| EV / EBITDA | 17.65 |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.96, with a Debt / Equity ratio of 0.78.
| Current Ratio | 1.96 |
| Quick Ratio | 1.59 |
| Debt / Equity | 0.78 |
| Debt / EBITDA | 7.55 |
| Debt / FCF | -4.66 |
| Interest Coverage | -0.14 |
Financial Efficiency
Return on equity (ROE) is 0.01% and return on invested capital (ROIC) is -0.20%.
| Return on Equity (ROE) | 0.01% |
| Return on Assets (ROA) | -0.06% |
| Return on Invested Capital (ROIC) | -0.20% |
| Return on Capital Employed (ROCE) | -0.12% |
| Weighted Average Cost of Capital (WACC) | 4.00% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.68 |
| Inventory Turnover | 5.20 |
Taxes
| Income Tax | -7,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -10.44% in the last 52 weeks. The beta is 0.19, so Welgene Biotech's price volatility has been lower than the market average.
| Beta (5Y) | 0.19 |
| 52-Week Price Change | -10.44% |
| 50-Day Moving Average | 17.39 |
| 200-Day Moving Average | 18.98 |
| Relative Strength Index (RSI) | 68.54 |
| Average Volume (20 Days) | 17,180 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Welgene Biotech had revenue of TWD 381.82 million and -387,000 in losses. Loss per share was -0.02.
| Revenue | 381.82M |
| Gross Profit | 161.62M |
| Operating Income | -531,000 |
| Pretax Income | 16,000 |
| Net Income | -387,000 |
| EBITDA | 15.55M |
| EBIT | -531,000 |
| Loss Per Share | -0.02 |
Balance Sheet
The company has 202.29 million in cash and 218.06 million in debt, with a net cash position of -15.77 million or -0.68 per share.
| Cash & Cash Equivalents | 202.29M |
| Total Debt | 218.06M |
| Net Cash | -15.77M |
| Net Cash Per Share | -0.68 |
| Equity (Book Value) | 279.90M |
| Book Value Per Share | 11.80 |
| Working Capital | 147.61M |
Cash Flow
In the last 12 months, operating cash flow was 20.63 million and capital expenditures -67.45 million, giving a free cash flow of -46.82 million.
| Operating Cash Flow | 20.63M |
| Capital Expenditures | -67.45M |
| Depreciation & Amortization | 16.08M |
| Net Borrowing | 19.29M |
| Free Cash Flow | -46.82M |
| FCF Per Share | -2.01 |
Margins
Gross margin is 42.33%, with operating and profit margins of -0.14% and -0.10%.
| Gross Margin | 42.33% |
| Operating Margin | -0.14% |
| Pretax Margin | 0.00% |
| Profit Margin | -0.10% |
| EBITDA Margin | 4.07% |
| EBIT Margin | -0.14% |
| FCF Margin | n/a |
Dividends & Yields
Welgene Biotech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -0.09% |
| FCF Yield | -10.89% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on August 17, 2018. It was a forward split with a ratio of 1.08.
| Last Split Date | Aug 17, 2018 |
| Split Type | Forward |
| Split Ratio | 1.08 |
Scores
Welgene Biotech has an Altman Z-Score of 1.85 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.85 |
| Piotroski F-Score | 4 |